Quantcast

Latest Oncolytic virus Stories

2014-06-10 12:31:14

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Recurrent Malignant Glioma - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/diseases/recurrent_malignant_glioma_pipeline_review_h1_2013.html Recurrent Malignant Glioma - Pipeline Review, H1 2014SummaryGlobal Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H1 2014', provides an overview of the Recurrent Malignant Glioma's therapeutic pipeline.This report...

2014-06-02 08:29:32

Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered THOUSAND OAKS, Calif., June 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th...

2014-06-02 08:29:05

CALGARY, June 2, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Jefferies 2014 Global Healthcare Conference in a session on Tuesday June 3(rd), 2014 at 4:00 p.m. ET. The conference takes place from June 2(nd) to 5(th) in New York, NY. A live audio link to the webcast session will be available at: http://wsw.com/webcast/jeff82/ONCY or on the company's website at...

2014-05-20 08:31:42

CALGARY, May 20, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN(®) to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org. The conference is being held from May 30(th) to June 3(rd), 2014 in Chicago, Illinois. "Treatment...

herpes virus attack a brain tumor cell
2014-05-18 03:00:47

Harvard Stem Cell Institute (HSCI) Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat. The work, led by Khalid...

2014-05-08 08:31:49

CALGARY, May 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the first quarter ended March 31, 2014. "During the quarter we reported additional data from our head and neck study which will help us with the design of our proposed registration study for discussion with regulators," said Dr. Brad Thompson, President and CEO of Oncolytics. "We also took steps to...

2014-04-14 12:33:05

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular...

2014-04-14 12:33:03

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster authored by Bolton, et al was presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein (YAP-1) in head and neck cancer," covered preclinical research focused on identifying biomarkers...

2014-04-11 08:24:10

CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that...

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related